-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42

Benzinga·07/01/2026 13:25:55
Listen to the news
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $20 to $42.